The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is \>0.3 nanomolar (nM).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Who Experience At Least One Adverse Event (AE)
Timeframe: Up to approximately 297 days
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 57 days
Serum Area Under the Concentration-Time Curve of MK-2214 from Time 0 to 28 Hours (AUC0-28) After First and Third Dose
Timeframe: At designated time points (up to 85 days)
Serum Maximum Concentration (Cmax) of MK-2214 After First and Third Dose
Timeframe: At designated time points (up to 85 days)
Serum Time to Maximum Concentration (Tmax) of MK-2214 After First and Third Dose
Timeframe: At designated time points (up to 85 days)
Serum Apparent Terminal Half-Life (t1/2) of MK-2214 After First and Third Dose
Timeframe: At designated time points (up to 85 days)
Concentration of MK-2214 in Cerebrospinal Fluid (CSF) at Day 85 (C85d)
Timeframe: Day 85
Percentage change from baseline to Day 29 in free phospho-tau in CSF
Timeframe: Baseline and Day 29 pre-dose
Percentage change from baseline to Day 85 in free phospho-tau in CSF
Timeframe: Baseline and Day 85